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Abstract. The eye is a rare site for disseminated malignan-
cies; nevertheless, several tumors may metastasize to ocular 
structures. Few cases of urothelial and bladder cancer with 
eye involvement have been described in the literature thus 
far. The rarity of metastatic ocular localization implies an 
accurate differential diagnosis among the possible primary 
tumor sites. However, a specific diagnostic algorithm is not 
currently available, nor a defined therapeutic approach. Eye 
metastases are associated with advanced disease and poor 
prognosis. Physicians should be made aware of the possibility 
of eye involvement in patients with a past medical history of 
urothelial bladder cancer associated with ocular symptoms. 
The present case reports discusses the first documented case, 
to the best of our knowledge, of an urothelial bladder cancer 
metastasizing to the retro bulbar region that infiltrates the 
lacrimal gland. Furthermore, the report provides a systematic 
qualitative review of the current literature on eye metastases 
from urothelial bladder cancer using the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses.
Introduction
Bladder cancer is the ninth cause of tumor in the world and the 
second most common genitourinary malignancy. Urothelial 
carcinoma represents 90% of all primary bladder tumors (1). 
Half of patients affected by these tumors, will develop local 
recurrence or distant metastases after radical surgery and 
treatment in this setting remains exclusively palliative. Lymph 
nodes, liver, lung and bones represent the metastatic sites with 
higher incidence (2). The eye is a rare site for disseminated 
malignancies because of the absence of a lymphatic system and 
metastases may occur by haematogenous spread (3). Therefore, 
eye structures with the highest vascular supply are more likely 
affected, with an incidence from 1 to 13% (2). Breast cancer 
is the most common primary tumor metastasizing to the eye, 
followed in order of frequency by: Lung cancer, gastrointes-
tinal tumors, and less commonly, thyroid, prostate, kidney, 
testicles, pancreatic, ovarian and liver cancer (4). Eye metas-
tases comprise both orbital (bone, muscle and fat) and ocular 
(mainly uveal) localizations (5,6). Majority of eye metastases 
in adults are located in the uvea and mainly in the choroid and 
orbital metastases are less frequent than uveal metastases (5). 
Generally, they onset as synchronous or metachronous local-
izations in patients with multiple metastatic sites and life 
expectancy is very poor. Twenty-three cases of urothelial or 
bladder tumors with eye metastases have been described in 
literature so far (2,4-23). Here we report the first documented 
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case, to our knowledge, of an urothelial-bladder cancer 
metastasizing to the retro‑bulbar region and infiltrating the 
lacrimal gland. Furthermore, we provide a systematic qualita-
tive review of the current literature on eye metastases from 
urothelial bladder cancer using the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) (24). 
Finally, we aim to clarify the features, medical interventions, 
outcomes and we try to describe the natural course of the 
disease in this uncommon group of patients.
Case report
A 70 years old man came to the hospital in March 2017 because 
of visual disorders in the right eye, diplopia and diffuse pain 
in retro-bulbar region. His past medical history was charac-
terized by chronic obstructive pulmonary disease (COPD) 
on treatment with Broncho-dilatators and arterial hyperten-
sion on treatment with ACE-inhibitor. In June 2014, patient 
had received radical cystectomy with lymphadenectomy for 
grade 3, urothelial bladder cancer, stage pT4N0M0. Despite 
preoperative staging detected a muscle invasive cancer, the 
patient strongly preferred a surgical approach instead of 
neoadjuvant chemotherapy. After radical surgery, adjuvant 
chemotherapy with cisplatin plus gemcitabine combination 
was administered for 4 cycles. At the time of hospitalization, 
the patient was undergoing to a follow up program that was 
negative for both local recurrence and distant metastases up 
to six months before. Eye clinical examination detected any 
cystic neo-formation but evidenced reduced motility. At the 
abdomen palpation liver was at 2.5 cm from the right costal 
margin with an irregular surface. Complete blood count was 
within normal limits and biochemical evaluation showed liver 
impairment: Aspartate aminotransferase 470 U/l, alanine 
aminotransferase 527 U/l, gamma-glutamyl transferase 
435 U/l. Contrast-enhanced computed tomography (CT) of 
the orbit showed an involvement of the right periorbital fat, 
retro bulbar spaces and lacrimal gland. Excisional biopsy was 
performed and samples from retro‑bulbar fibro‑adipose tissue 
and lacrimal gland were collected. Histological examination 
showed neoplastic infiltration of fibro adipose tissue charac-
terized by diffuse population of cellular elements with a high 
eosinophilic cytoplasm and eccentric nuclei. Diffuse angio-
lymphatic invasion was also present. Immunohistochemistry 
stains were positive for GATA3, CKAE1/AE3, CK5, CK7, 
CK20, CD138, DNP63 and negative for LCA and CD79α 
(Fig. 2). Finally, the histological examination was diagnostic 
for retro bulbar metastases from urothelial carcinoma. 
Subsequently, full body CT scan showed multiple liver 
metastases. Due to the patient's clinical condition (Eastern 
Cooperative Oncology Group-ECOG performance status 2) 
and the liver impairment evidenced by the biochemistry, no 
chemotherapy was administered and best supportive care 
was started. Unfortunately, because of widespread metastatic 
disease the patient died three months after the diagnosis of the 
ocular involvement.
Patient's medical history including comorbidities, 
concomitant medications, bladder cancer diagnosis, previous 
treatments and ocular metastasis detection were taken from 
clinical records. Written informed consent for the case publi-
cation was obtained from the patient at the time of retro-bulbar 
metastasis histological confirmation. The Ethics Committee 
approved all procedures. 
Review criteria. A systematic review of the literature was 
performed in compliance with the PRISMA guidelines. 
Screening was performed by reviewing article titles or full text 
up to February 2018 using electronic database: MEDLINE 
and WEB OF SCIENCE. The primary search terms included 
‘ocular metastasis’, ‘eye metastasis’ and ‘urothelial bladder 
cancer’ in the article titles. The extracted citations were then 
screened for duplicates. Later operators ‘and’ and ‘or’ were 
applied on the extracted records by use of the terms ‘urothe-
lial,’ ‘bladder’, ‘cancer’, ‘ocular’, ‘eye’, ‘metastasis’ to narrow 
the scope of the review (Fig. 1). Twenty-four articles met 
eligibility criteria for our qualitative systematic review and 23 
previously reported cases were identified. This population was 
described for median age, gender, ocular site, both systemic 
and ocular specific treatment. We also evaluated the time to 
ocular metastases, defined as the time elapsed between the 
urothelial bladder cancer diagnosis and the ocular metastases 
occurrence. Overall survival from ocular metastases was 
defined as the time elapsed from the eye involvement to death. 
Kaplan Meier analysis for survival was performed using 
GraphPad Prism 5.04 for Windows (GraphPad Software, Inc., 
La Jolla, CA, USA). This evaluation included only patients 
whose survival data were available.
Discussion
Eye metastases are uncommon, accounting for between 
2.5 and 8.1% of all orbital space-occupying lesions (25). 
The majorities are adenocarcinoma and the most common 
primary site is breast (26). Prostate, colon, and lung cancer 
can also metastasize to the eye. Bladder carcinoma is an 
extremely rare source of eye metastases. Since the first case 
reported in 1965, only 23 additional cases of eye metastases 
from bladder cancer have been reported in literature prior 
to the present case. This case is extremely rare since the 
patient developed retro bulbar metastasis with lacrimal 
gland infiltration and it is the first described in literature. 
Seventy per cent of bladder tumors do not extend beyond 
the lamina propria at the time of diagnoses. Among the 
patients treated with radical cystectomy 57% are character-
ized by muscular infiltration while the remaining 43% show 
non‑infiltrative disease that progress to an infiltrative carci-
noma. Around a quarter of patients receiving radical surgery 
has lymph-nodes involvement and one third of the cases with 
infiltrative carcinoma could have micro metastatic disease 
at the time of primary tumor treatment (25). In the present 
case patient obtained cystectomy and lymphadenectomy 
three years before the occurrence of retrobulbar and liver 
metastases. The current state of the art for muscle invasive 
bladder cancer treatment is neoadjuvant, platinum-based 
chemotherapy. Nevertheless, in this case the patient chose 
an immediate surgical approach. At the time of diagnosis, 
he showed pT4N0M0, G3 urothelial bladder carcinoma. 
Despite of infiltrative disease no lymph nodes were involved 
at the time of surgery. Notably, the patient received adju-
vant chemotherapy but he developed multiple liver and 
ocular metastases. Therefore, the concept of an aggressive, 
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micro-metastatic disease from the beginning should be taken 
into account. Usually, bladder cancer metastasizes to lymph 
nodes, liver, lung and bones. However this case is particular 
because widespread disease was diagnosed without lymph 
node involvement, suggesting an hematogenous diffusion. 
The median age of patients with eye metastases from bladder 
cancer reported so far is 58 years (range, 43-75) (Table I). 
In the majority of cases, eye involvement is metachronous 
and is associated to other metastatic sites (Table I). Five 
of 24 cases are reported as synchronous metastases but 4 
out of 19 described as metachronous show a time to eye 
metastases less than 1 month. At the light of this observa-
tion, it should be recommended a careful and correct staging 
of the disease at the time of diagnosis. In fact, in patients 
with ocular symptoms the probability of eye involvement 
should be considered, even if it is uncommon. Clinical 
presentation may differ depending on ocular or orbital local-
ization and it could be peculiar for each metastatic site (5). 
In fact exophthalmos, proptosis and pain are likely related 
to orbital involvement. Moreover, as reported in literature, 
other signs or symptoms like visual disorders, diplopia, 
paralysis of the VI cranial nerve, hyperesthesia of the 
trigeminal nerve, amaurosis, inflamed conjunctiva, retinal 
detachment and even palpable mass should not be underes-
timated. Because of the rarity of eye involvement, there is 
no diagnostic algorithm: Specific clinical visit and CT scan 
are recommended and differential diagnosis includes: Retro 
bulbar region or lacrimal gland tumors, retinal abscess, 
metastasis from carcinoma, and granuloma (25). In this 
patient, retro-bulbar region biopsy was performed because 
of visual disorders that occurred before liver involvement 
diagnosis. Only few patients among the cases reported in 
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol used for the systematic review.
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literature had received a cytological or histological exami-
nation. Immunohistochemical staining (IHC) of the nuclei 
of the tumor cells was intensely positive for transcription 
factor GATA3, which is specific for urothelial and breast 
carcinoma. The cells were also strongly immunoreactive 
for epithelial markers CKAE1/AE3, CK5, CK7 and CK20. 
Co-expression of CK7 and CK20 is a differential feature of 
urothelial carcinoma and excludes breast carcinoma that is 
positive only for CK7. Positive CD138, DNP63 and nega-
tive LCA, CD79α completed the diagnosis. Metastatic eye 
involvement indicates a later stage of the disease with an 
extremely poor prognosis. In the literature, median time 
to eye metastases is 11 months (Table I) and the median 
overall survival is 3 months (Fig. 3). In the present case, no 
chemotherapy was administered due to the poor ECOG PS 
and liver impairment showed by laboratory examinations. 
There is no specific treatment for eye metastases and the 
aim of the cure is palliative. Orbital and ocular metastatic 
sites could receive theoretically different approaches but 
treatment should be evaluated case by case because of the 
lack of evidences. Only 5 out of 24 patients reported so far 
received local radiotherapy and 1 out of 24 received surgical 
decompression in order to improve the ocular symptoms. 
Conversely, the majority of patients received chemotherapy 
for metastatic disease without clinical or survival benefit.
To the best of our knowledge, this is the first qualitative 
systematic review about eye metastases caused by urothelial 
bladder cancer. Furthermore, the case described in this article 
represents the first report of retro‑bulbar involvement that 
infiltrates the lacrimal gland from urothelial bladder cancer. 
Another novelty of this case is represented by an accurate 
IHC evaluation in order to clarify the differential diagnoses 
Figure 2. Hematoxylin and eosin examination revealed (A) neoplastic infiltration of fibro‑adipose tissue characterized by diffuse population of cellular elements 
with a high eosinophilic cytoplasm and eccentric nuclei. Immunohistochemistry showed positive staining for (B) CK7, (C) Cluster of Differentiation-138, 
(D) GATA3, (E) CK20 and (F) dnp63. Magnification, x400. CK, cytokeratin.
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among the different primary tumor sites. Muscular infiltra-
tive bladder cancer should be considered as a potential micro 
metastatic disease since the beginning. Therefore, Oncologist 
should be aware about the possibility of eye involvement in 
patients with a past medical history of urothelial bladder 
cancer associated with eye disorders. Multidisciplinary 
approach is required for an early detection of this condition 
that should lead to a prompt therapeutic intervention. The 
rarity of metastatic eye localization does not provide high 
level of evidence for a specific treatment. Actually, majority 
of patients receive chemotherapy with poor outcomes. 
Molecular and biological aspects of both urothelial bladder 
cancer and metastatic sites should be further investigated in 
order to improve therapeutic options and patients' prognosis.
Table I. Summary of reported cases of urothelial-bladder cancer metastasizing to the eye.
    Time to
    ocular  Treatment
 Age  Eye metastasis  for ocular OS
Author, year (years) Gender localization (months) Treatment metastasis (months) (Refs.)
Smiley, 1965 75 M Retrobulbar, L Synchronous BSC No 8 (7)
Resnick et al, 1975 46 M Orbit, L 1 ADRIA+5FU No 4 (8)
Resnick et al, 1975 51 M Choroid, R 15 No RT 4 (8)
Cieplinski et al, 1982 57 M Choroid, B 8 CDDP+ RT 0.5 (9)
     ADRIA+CTX
Krauss et al, 1982 64 F Orbit, R 15 No RT 1 (10)
Prats et al, 1989 58 M Orbit, L Synchronous No Surgical 4 (11)
      decompression
Felip et al, 1991 58 M Orbit 0,5 NA No 3 (12)
Felip et al, 1991 62 M Orbit 36 NA No LF (12)
Angulo et al, 1991 61 M Retro-orbital 11 BSC No 0.9 (13)
Hugkulstone et al, 1994 45 M Orbit, B Synchronous MVAC RT 5 (14)
Scott and Williams, 1994 NA NA Orbit Synchronous NA NA 8 (15)
Fynn-Thompson et al, 68 M Orbital +  48 BSC No 1 (16)
2003   optic nerve, L
Nabi et al, 2002 43 F Optic canal L 6 MVAC No 3 (17)
Nabi et al, 2002 79 M Choroid R 8 MVAC No 1.6 (17)
Amemiya et al, 2002 55 M Orbital B NA NA NA NA (18)
Amemiya et al, 2002 73 M Orbital R NA NA NA NA (18)
Souza Filho et al, 2005 53 M Orbit L 3 weeks BSC no 1 (19)
Levecq et al, 2007 58 M Choroidal 96 no Enucleation,  7 (20)
      RT
Lin et al, 2007 60 M Orbit R 8 MVAC No Alive (4)
       at 6
Wettach and Steele 2008 66 M Orbit R Synchronous CBDCA+GEM No 1 (21)
Mitsui et al, 2014  48 M Choroid R 17 MVAC No 5 (2)
SooHoo et al, 2012  53 F Orbit R 1 BSC No 3 (22)
Magrath et al, 2015 57 F Orbit L Synchronous BSC No LF (23)
Present case 70 M Retrobulbar R,  33 BSC No 3 -
   lacrimal gland
NA, not available; M, male; F, female; L, left; R, right; B, bilateral; BSC, best supportive care; ADRIA, adriamycin; 5FU, 5‑fluoroiracil; CDDP, 
cisplatin; CTX, cyclophosphamide; MVAC, methotrexate + vinblastine + adriamycin + cisplatin; CBDCA, carboplatin; GEM, gemcitabine; 
RT, radiotherapy; OS, overall survival; LF, lost to follow up.
Figure 3. Kaplan Meier curve for overall survival from the occurrence of 
ocular metastasis.
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